Trade Names:Airet- Solution for inhalation 0.083% (as sulfate)
Trade Names:Proventil- Tablets 2 mg (as sulfate)- Tablets 4 mg (as sulfate)- Syrup 2 mg (as sulfate) per 5 mL- Aerosol Each actuation delivers 90 mcg albuterol- Solution for inhalation 0.083% (as sulfate)- Solution for inhalation 0.5% (as sulfate)
Trade Names:Proventil HFA- Aerosol Each actuation delivers 90 mcg albuterol (as sulfate)
Trade Names:Ventolin- Tablets 2 mg (as sulfate)- Tablets 4 mg (as sulfate)- Syrup 2 mg (as sulfate) per 5 mL- Solution for inhalation 0.5% (as sulfate)
Trade Names:Ventolin Nebules- Solution for inhalation 0.083% (as sulfate)
Trade Names:Ventolin Rotacaps- Capsules for inhalation 200 mcg microfine (as sulfate)Airomir (Canada)Apo-Salvent (Canada)Apo-Salvent CFC Free (Canada)Gen-Salbutamol Respirator Solution (Canada)Gen-Salbutamol Sterinebs P.F. (Canada)ratio-Salbutamol HFA (Canada)Sandoz Salbutamol (Canada)Ventolin Diskus (Canada)Ventolin Oral Liquid (Canada)
Produces bronchodilation by relaxing bronchial smooth muscle through beta-2 receptor stimulation.
Rapidly absorbed; T max is 2 h; C max is about 18 ng/mL.Inhalation
Less than 20% absorbed; T max is 0.5 h; C max is 2.1 ng/mL.
T ½ is 5 to 6 h. 76% recovered in urine over 3 days with 60% as metabolites; 4% excreted in feces.
Within 30 min.Inhalation
Within 5 min.
4 to 8 h.Inhalation
3 to 6 h.
Prevention and treatment of reversible bronchospasm associated with asthma and other obstructive pulmonary diseases.
Adjunctive treatment of hyperkalemia in patients undergoing dialysis.
1 to 2 inhalations every 4 to 6 h.Prevention of exercise-induced bronchospasm
2 inhalations 15 min before exercise.Inhalation SolutionAdults and children older than 2 yr of age
2.5 mg/dose 3 to 4 times/day by nebulization.Children 2 to 12 yr of age ( AccuNeb )
1.25 mg or 0.63 mg 3 to 4 times/day by nebulization.OralAdults and Children older than 12 yr of age
PO 2 to 4 mg/dose 3 to 4 times/day. Do not exceed 32 mg/day.Children 6 to 12 yr of age
PO 2 mg/dose 3 to 4 times/day. Do not exceed 24 mg/day.Children 2 to 6 yr of age
PO 0.1 to 0.2 mg/kg/dose 3 times/day. Do not exceed 12 mg/day.Adults and Children older than 12 yr of age, extended-release ( Proventil Repetabs )
PO 4 to 8 mg every 12 h. May be cautiously increased stepwise to a max of 16 mg twice daily (max, 32 mg/day).Children 6 to 12 yr of age, extended-release ( Proventil Repetabs )
PO 4 every 12 h. May be cautiously increased stepwise to a max of 12 mg twice daily.SyrupAdults and Children alder than 12 yr of age
2 or 4 mg (1 to 2 tsp) 3 or 4 times/day. Doses of above 4 mg 4 times/day may be appropriate when patient fails to respond.Children 6 to 12 yr of age
2 mg (1 tsp) 3 or 4 times/day. Doses of 2 mg 4 times/day may be cautiously increased. Do not exceed 24 mg/day in divided doses.Children 2 to 6 yr of age
Initiate at 0.1 mg/kg 3 times/day. Dose may be increased 2 mg 3 times/day. Do not exceed 2 mg 3 times/day. Dose may be increased to 0.2 mg/kg 3 times/day, but not to exceed 4 mg 3 times/day.Elderly and those sensitive to beta-adrenergic stimulation
Restrict initial dose to 2 mg (1 tsp) 3 or 4 times/day. Individualize dosage thereafter.
Store at room temperature. Refrigeration of syrup improves palatability.
Severe bronchospasms may be produced in asthmatic patients taking albuterol.Digoxin
Albuterol may decrease serum digoxin levels.Diuretics
ECG changes and hypokalemia associated with these diuretics may worsen with albuterol coadministration.
None well documented.
Palpitations; tachycardia; elevated BP; chest tightness; angina.
Tremor; dizziness; hyperactivity; nervousness; headache; insomnia; weakness; drowsiness; restlessness.
Dry mouth; throat irritation.
Nausea; vomiting; heartburn; diarrhea.
Cough; bronchospasm; wheezing; dyspnea.
Flushing; sweating; anorexia; unusual sensory changes.
Category C .
Albuterol aerosol and inhalation powder in children younger than 4 yr of age and albuterol solution for inhalation in children younger than 2 yr of age not established.
May inhibit uterine contractions.
Toxic symptoms may occur in patients with CV disorders.
CNS stimulation may occur; use cautiously in patients with history of seizures or hyperthyroidism.
Dosage adjustment of insulin or oral hypoglycemic agent may be required.
Paradoxical bronchospasm and cardiac arrest have been associated with excessive inhalant use.
Decreases in potassium levels have occurred.
If previously effective dose fails to provide relief, therapy may need to be reassessed.
Tremor, palpitations, tachycardia, elevated BP, seizures.
Copyright © 2009 Wolters Kluwer Health.